Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAUL R SIEBER

Allopathic & Osteopathic Physicians Urology

NPI
1851375026
CMS profile
174335
Location
LANCASTER, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$68,752.86

180 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAUL R SIEBER

NPI 1851375026 · CMS profile ID 174335

Allopathic & Osteopathic Physicians / Urology

LANCASTER, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1851375026?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAUL R SIEBER, NPI 1851375026, CMS profile ID 174335. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1851375026?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). PAUL R SIEBER, NPI 1851375026, CMS profile ID 174335. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1851375026?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
PAUL R SIEBER, NPI 1851375026, CMS profile ID 174335, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1851375026?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

180 matching records · $68,752.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 180 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 180.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Astellas Pharma US Inc $14.9805/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655761887 CMS
TOLMAR Pharmaceuticals, Inc. $17.9505/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675457907 CMS
Merck Sharp & Dohme Corporation $24.6305/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695528219 CMS
Clovis Oncology, Inc. $90.9505/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688687351 CMS
PFIZER INC. $127.0705/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672059797 CMS
Ferring Pharmaceuticals Inc. $55.3405/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655218309 CMS
Ferring Pharmaceuticals Inc. $29.4505/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655218311 CMS
Ferring Pharmaceuticals Inc. $10.6205/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655218313 CMS
Ferring Pharmaceuticals Inc. $42.2305/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655218315 CMS
Ferring Pharmaceuticals Inc. $17.8905/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655218317 CMS
Ferring Pharmaceuticals Inc. $351.0305/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655218307 CMS
Bayer HealthCare Pharmaceuticals Inc. $18.0504/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628430317 CMS
Boston Scientific Corporation $37.7504/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709057481 CMS
Boston Scientific Corporation $70.7204/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709057485 CMS
Boston Scientific Corporation $71.2404/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709057487 CMS
Boston Scientific Corporation $241.9204/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709057489 CMS
Boston Scientific Corporation $982.0004/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709057491 CMS
Boston Scientific Corporation $38.2704/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709057483 CMS
Janssen Biotech, Inc. $275.2704/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658716375 CMS
Janssen Biotech, Inc. $46.7404/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658716377 CMS
Janssen Biotech, Inc. $28.0404/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658716381 CMS
Janssen Biotech, Inc. $32.7204/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658716383 CMS
Ferring Pharmaceuticals Inc. $5,680.0004/26/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655218305 CMS
Sun Pharmaceutical Industries Inc. $14.0304/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704637909 CMS
Coloplast Corp $12.5804/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696982861 CMS
PFIZER INC. $9.6804/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671980511 CMS
PFIZER INC. $11.4204/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671957833 CMS
Astellas Pharma US Inc $10.6904/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655761885 CMS
Astellas Pharma US Inc $16.2804/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655761883 CMS
AbbVie, Inc. $21.9504/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648145265 CMS
PFIZER INC. $30.1603/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671897437 CMS
Sun Pharmaceutical Industries Inc. $14.6103/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704637907 CMS
Astellas Pharma US Inc $3,630.0003/26/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655761877 CMS
Astellas Pharma US Inc $125.0003/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655761879 CMS
Astellas Pharma US Inc $834.6903/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655761881 CMS
Astellas Pharma Global Development $6,285.0003/25/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 641930283 CMS
Astellas Pharma Global Development $73.6403/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 641930285 CMS
Astellas Pharma Global Development $9.0403/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 641930287 CMS
Bayer HealthCare Pharmaceuticals Inc. $7.2503/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628464351 CMS
PFIZER INC. $2,750.0003/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671899021 CMS
Ferring Pharmaceuticals Inc. $13.0403/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655218303 CMS
PFIZER INC. $96.5103/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671899019 CMS
Ferring Pharmaceuticals Inc. $14.0803/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655218301 CMS
Janssen Biotech, Inc. $7.4003/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658716371 CMS
Astellas Pharma US Inc $3,630.0003/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655761871 CMS
Astellas Pharma US Inc $91.0803/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655761873 CMS
Astellas Pharma US Inc $1,015.6203/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655761875 CMS
Janssen Biotech, Inc. $2.5003/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658716367 CMS
Astellas Pharma US Inc $10.1403/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655761869 CMS
Astellas Pharma Global Development $800.2003/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 641930275 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $68,752.86 180
PY2020 $45,776.52 82
PY2021 $63,326.54 142
PY2022 $98,813.64 191
PY2023 $123,980.70 207
PY2024 $118,775.57 183
PY2025 $111,221.18 194

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $5,223.19 10
PY2025 Principal investigator $1,566,575.84 119
PY2024 Recipient $5,080.00 3
PY2024 Principal investigator $2,395,471.29 191
PY2023 Recipient $1,650.00 5
PY2023 Principal investigator $1,577,803.80 257
PY2022 Principal investigator $1,379,025.92 340
PY2021 Recipient $7,000.00 1
PY2021 Principal investigator $1,381,716.11 213
PY2020 Principal investigator $1,840,393.81 304
PY2019 Recipient $63.72 1
PY2019 Principal investigator $1,818,552.15 321

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

129 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $37,491.28 12/31/2025 Non-covered Recipient Entity
Lancaster Urology
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232926515
Principal investigator 1 Merck Sharp & Dohme LLC $25,308.02 12/29/2025 Non-covered Recipient Entity
Lancaster Urology
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232927067
Principal investigator 1 Janssen Research & Development, LLC $9,087.00 12/25/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LL
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 1175379319
Principal investigator 1 Janssen Research & Development, LLC $7,703.00 12/22/2025 Non-covered Recipient Entity
KEYSTONE UROLOGY SPECIALISTS
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175342264
Principal investigator 1 Janssen Research & Development, LLC $880.00 12/18/2025 Non-covered Recipient Entity
KEYSTONE UROLOGY SPECIALISTS
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175342234
Principal investigator 1 Janssen Research & Development, LLC $9,955.00 12/01/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LL
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 1175379276
Principal investigator 1 Janssen Research & Development, LLC $11,016.00 11/28/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LL
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 1175379338
Principal investigator 1 Janssen Research & Development, LLC $173.00 11/27/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LL
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175379240
Principal investigator 1 Janssen Research & Development, LLC $173.00 11/27/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LL
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175379256
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,550.00 11/14/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
PROVONE STUDY No dispute reported 06/30/2026 1247892616
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,600.00 11/14/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
PROVONE STUDY No dispute reported 06/30/2026 1247892620
Principal investigator 1 Dendreon Pharmaceuticals LLC $800.00 11/14/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
PROVONE STUDY No dispute reported 06/30/2026 1247892623
Principal investigator 1 PFIZER INC. $46,207.89 11/10/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228725090
Principal investigator 1 PFIZER INC. $46,207.89 11/08/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727231
Principal investigator 1 Sumitomo Pharma America, Inc. $833.60 11/05/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE UROLOGY SPECIAL
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654857
Principal investigator 1 Janssen Research & Development, LLC $886.00 11/03/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LL
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175379284
Recipient PFIZER INC. $330.00 11/03/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727783
Principal investigator 1 PFIZER INC. $92,415.77 10/30/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726634
Principal investigator 1 PFIZER INC. $92,415.77 10/29/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727393
Principal investigator 1 Janssen Research & Development, LLC $42,000.00 10/24/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LL
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 1175379346
Recipient PFIZER INC. $940.00 10/18/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726504
Principal investigator 1 Janssen Research & Development, LLC $107.00 10/17/2025 Non-covered Recipient Entity
Lancaster Uro
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175265689
Principal investigator 1 PFIZER INC. $6,230.62 10/14/2025 Non-covered Recipient Entity
KEYSTONE UROLOGY SPECIALISTS
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228737191
Principal investigator 1 Janssen Research & Development, LLC $442.00 10/13/2025 Non-covered Recipient Entity
KEYSTONE UROLOGY SPECIALISTS
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175342165
Principal investigator 1 Janssen Research & Development, LLC $7,703.00 10/13/2025 Non-covered Recipient Entity
KEYSTONE UROLOGY SPECIALISTS
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175342181
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $881.26 10/10/2025 Non-covered Recipient Entity
Keystone Urology Specialists
BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients No dispute reported 06/30/2026 1225419857
Principal investigator 1 PFIZER INC. $21,499.00 10/08/2025 Non-covered Recipient Entity
The Centers for Advanced Urology LLP dba Keystone Urology Specialists
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 No dispute reported 06/30/2026 1228741837
Principal investigator 1 Dendreon Pharmaceuticals LLC $500.00 09/26/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
PROVONE STUDY No dispute reported 06/30/2026 1247892479
Principal investigator 1 Dendreon Pharmaceuticals LLC $50.00 09/26/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
PROVONE STUDY No dispute reported 06/30/2026 1247892483
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,600.00 09/26/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
PROVONE STUDY No dispute reported 06/30/2026 1247892486
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,600.00 09/26/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
PROVONE STUDY No dispute reported 06/30/2026 1247892489
Principal investigator 1 Dendreon Pharmaceuticals LLC $500.00 09/26/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
PROVONE STUDY No dispute reported 06/30/2026 1247892492
Principal investigator 1 Dendreon Pharmaceuticals LLC $50.00 09/26/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
PROVONE STUDY No dispute reported 06/30/2026 1247892496
Principal investigator 1 Dendreon Pharmaceuticals LLC $50.00 09/26/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
PROVONE STUDY No dispute reported 06/30/2026 1247892499
Principal investigator 1 Dendreon Pharmaceuticals LLC $500.00 09/26/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
PROVONE STUDY No dispute reported 06/30/2026 1247892503
Principal investigator 1 Janssen Research & Development, LLC $2,699.00 09/26/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LL P
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175379296
Principal investigator 1 Janssen Research & Development, LLC $706.00 09/26/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LL P
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175379304
Principal investigator 1 Janssen Research & Development, LLC $880.00 09/08/2025 Non-covered Recipient Entity
KEYSTONE UROLOGY SPECIALISTS
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175342254
Principal investigator 1 Merck Sharp & Dohme LLC $521.80 08/31/2025 Non-covered Recipient Entity
Lancaster Urology
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232926559
Principal investigator 1 PFIZER INC. $46,207.89 08/21/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726484
Principal investigator 1 PFIZER INC. $46,207.89 08/20/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726674
Principal investigator 1 Janssen Research & Development, LLC $107.00 08/18/2025 Non-covered Recipient Entity
Lancaster Uro
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175265706
Principal investigator 1 PFIZER INC. $46,207.89 08/11/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727557
Principal investigator 1 PFIZER INC. $46,207.89 08/10/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228723642
Principal investigator 1 Janssen Research & Development, LLC $423.00 08/07/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LL P
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175379264
Principal investigator 1 PFIZER INC. $46,207.89 08/02/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727067
Principal investigator 1 Sumitomo Pharma America, Inc. $30.00 08/01/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE UROLOGY SPECIAL
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176641711
Principal investigator 1 Sumitomo Pharma America, Inc. $1,667.20 08/01/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE UROLOGY SPECIAL
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176641787
Principal investigator 1 Sumitomo Pharma America, Inc. $30.00 08/01/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE UROLOGY SPECIAL
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176641836
Principal investigator 1 PFIZER INC. $46,207.89 07/31/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228725990
Principal investigator 1 Janssen Research & Development, LLC $1,621.00 07/28/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LL P
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175379353
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 07/17/2025 Non-covered Recipient Entity
KEYSTONE UROLOGY SPECIALISTS
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175342173
Principal investigator 1 Sumitomo Pharma America, Inc. $833.60 07/09/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE UROLOGY SPECIAL
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176640400
Principal investigator 1 Janssen Research & Development, LLC $2,116.00 07/03/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LL P
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175379270
Principal investigator 1 Janssen Research & Development, LLC $706.00 07/03/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LL P
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175379327
Principal investigator 1 Janssen Research & Development, LLC $4,674.00 06/30/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LL P
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175379249
Recipient Dendreon Pharmaceuticals LLC $322.73 06/24/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891672
Principal investigator 2 Dendreon Pharmaceuticals LLC $3,550.00 06/24/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
ProvONE No dispute reported 06/30/2026 1247892234
Principal investigator 1 Janssen Research & Development, LLC $7,703.00 06/16/2025 Non-covered Recipient Entity
KEYSTONE UROLOGY SPECIALISTS
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175342202
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $453.13 06/12/2025 Non-covered Recipient Entity
Keystone Urology Specialists
BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients No dispute reported 06/30/2026 1225402505
Recipient Dendreon Pharmaceuticals LLC $25.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891649
Recipient Dendreon Pharmaceuticals LLC $322.73 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891653
Recipient Dendreon Pharmaceuticals LLC $322.73 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891656
Recipient Dendreon Pharmaceuticals LLC $1,800.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891660
Recipient Dendreon Pharmaceuticals LLC $30.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891664
Recipient Dendreon Pharmaceuticals LLC $800.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891669
Principal investigator 2 Dendreon Pharmaceuticals LLC $16,000.00 06/05/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC
ProvONE No dispute reported 06/30/2026 1247891953
Principal investigator 2 Dendreon Pharmaceuticals LLC $13,000.00 06/05/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC
ProvONE No dispute reported 06/30/2026 1247891957
Principal investigator 2 Dendreon Pharmaceuticals LLC $50.00 06/05/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
ProvONE No dispute reported 06/30/2026 1247892102
Principal investigator 2 Dendreon Pharmaceuticals LLC $3,550.00 06/05/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
ProvONE No dispute reported 06/30/2026 1247892106
Principal investigator 2 Dendreon Pharmaceuticals LLC $3,550.00 06/05/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
ProvONE No dispute reported 06/30/2026 1247892112
Principal investigator 2 Dendreon Pharmaceuticals LLC $3,600.00 06/05/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
ProvONE No dispute reported 06/30/2026 1247892119
Principal investigator 2 Dendreon Pharmaceuticals LLC $150.00 06/05/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
ProvONE No dispute reported 06/30/2026 1247892123
Principal investigator 2 Dendreon Pharmaceuticals LLC $800.00 06/05/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
ProvONE No dispute reported 06/30/2026 1247892126
Principal investigator 2 Dendreon Pharmaceuticals LLC $19,000.00 06/05/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC
ProvONE No dispute reported 06/30/2026 1247892192
Principal investigator 2 Dendreon Pharmaceuticals LLC $13,000.00 06/05/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC
ProvONE No dispute reported 06/30/2026 1247892197
Principal investigator 2 Dendreon Pharmaceuticals LLC $211.99 06/05/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC
ProvONE No dispute reported 06/30/2026 1247892201
Principal investigator 1 PFIZER INC. $46,206.12 06/02/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228751297
Principal investigator 1 PFIZER INC. $46,206.12 06/01/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753921
Principal investigator 1 PFIZER INC. $46,207.89 06/01/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755886
Principal investigator 1 Janssen Research & Development, LLC $94.00 05/19/2025 Non-covered Recipient Entity
KEYSTONE UROLOGY SPECIALISTS
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175342227
Principal investigator 1 Janssen Research & Development, LLC $3,028.00 05/19/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LL P
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175379224
Principal investigator 1 Janssen Research & Development, LLC $2,699.00 05/19/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LL P
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175379231
Principal investigator 1 Janssen Research & Development, LLC $107.00 05/16/2025 Non-covered Recipient Entity
Lancaster Uro
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175265682
Principal investigator 1 Janssen Research & Development, LLC $423.00 05/16/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LL P
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175379360
Principal investigator 1 PFIZER INC. $92,412.24 05/13/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752414
Recipient PFIZER INC. $330.00 05/13/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228770908
Principal investigator 1 PFIZER INC. $92,412.24 05/12/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752828
Principal investigator 1 PFIZER INC. $92,415.78 05/12/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754361
Principal investigator 1 Sumitomo Pharma America, Inc. $60.00 05/07/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE UROLOGY SPECIAL
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176634162
Principal investigator 1 Sumitomo Pharma America, Inc. $833.60 05/07/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE UROLOGY SPECIAL
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176634173
Principal investigator 1 Janssen Research & Development, LLC $5,856.00 04/25/2025 Non-covered Recipient Entity
THE CENTERS FOR ADVANCED UROLOGY LL P
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175379310
Principal investigator 1 Sumitomo Pharma America, Inc. $60.00 04/09/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE UROLOGY SPECIAL
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632579
Principal investigator 1 Sumitomo Pharma America, Inc. $3,394.40 04/09/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE UROLOGY SPECIAL
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632601
Principal investigator 1 Sumitomo Pharma America, Inc. $2,500.00 04/09/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE UROLOGY SPECIAL
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176632847
Principal investigator 1 Janssen Research & Development, LLC $221.00 03/31/2025 Non-covered Recipient Entity
KEYSTONE UROLOGY SPECIALISTS
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175342272
Principal investigator 1 Janssen Research & Development, LLC $880.00 03/31/2025 Non-covered Recipient Entity
KEYSTONE UROLOGY SPECIALISTS
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175342279
Principal investigator 1 MEDIVATION LLC. $120.00 03/25/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228776848
Principal investigator 1 MEDIVATION LLC. $150.00 03/25/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228778259
Principal investigator 1 Janssen Research & Development, LLC $107.00 03/13/2025 Non-covered Recipient Entity
Lancaster Uro
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175265698
Principal investigator 1 Janssen Research & Development, LLC $2,699.00 03/10/2025 Non-covered Recipient Entity
KEYSTONE UROLOGY SPECIALISTS
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175342194
Principal investigator 1 Janssen Research & Development, LLC $7,703.00 03/10/2025 Non-covered Recipient Entity
KEYSTONE UROLOGY SPECIALISTS
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175342285
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,400.00 03/05/2025 Non-covered Recipient Entity
KEYSTONE UROLOGY SPECIALISTS
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib Abiraterone Versus Placebo Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281) No dispute reported 06/30/2026 1185543945
Principal investigator 1 PFIZER INC. $15,402.04 03/04/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752410
Principal investigator 1 MEDIVATION LLC. $222.00 03/03/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228719957
Principal investigator 1 MEDIVATION LLC. $222.00 03/03/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228724696
Principal investigator 1 MEDIVATION LLC. $222.00 03/03/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774687
Principal investigator 1 MEDIVATION LLC. $222.00 03/03/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774691
Principal investigator 1 MEDIVATION LLC. $222.00 03/03/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775378
Principal investigator 1 MEDIVATION LLC. $1,008.00 03/03/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228776395
Principal investigator 1 MEDIVATION LLC. $1,008.00 03/03/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228778050
Principal investigator 1 MEDIVATION LLC. $1,008.00 03/03/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228784925
Principal investigator 1 MEDIVATION LLC. $1,008.00 03/03/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228786409
Principal investigator 1 PFIZER INC. $15,402.04 03/03/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754027
Principal investigator 1 PFIZER INC. $15,402.63 03/03/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754760
Principal investigator 1 Janssen Research & Development, LLC $4,709.00 02/28/2025 Non-covered Recipient Entity
KEYSTONE UROLOGY SPECIALISTS
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175342217
Principal investigator 1 PFIZER INC. $46,206.12 02/12/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752406
Principal investigator 1 PFIZER INC. $46,206.12 02/11/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752994
Principal investigator 1 PFIZER INC. $46,207.89 02/11/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754880
Principal investigator 1 Astellas Pharma Global Development $1,400.00 02/06/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234183427
Principal investigator 1 Janssen Research & Development, LLC $880.00 02/03/2025 Non-covered Recipient Entity
KEYSTONE UROLOGY SPECIALISTS
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175342186
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $503.13 01/30/2025 Non-covered Recipient Entity
Keystone Urology Specialists
BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients No dispute reported 06/30/2026 1225405204
Principal investigator 1 MEDIVATION LLC. $1,008.00 01/28/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228776078
Principal investigator 1 MEDIVATION LLC. $859.20 01/28/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228777133
Principal investigator 1 MEDIVATION LLC. $1,086.00 01/28/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228778420
Principal investigator 1 Janssen Research & Development, LLC $2,648.00 01/27/2025 Non-covered Recipient Entity
KEYSTONE UROLOGY SPECIALISTS
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175342210
Principal investigator 1 Janssen Research & Development, LLC $10,808.00 01/27/2025 Non-covered Recipient Entity
KEYSTONE UROLOGY SPECIALISTS
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175342245
Principal investigator 1 MEDIVATION LLC. $1,008.00 01/02/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228777779
Principal investigator 1 PFIZER INC. $46,206.12 01/02/2025 Non-covered Recipient Entity
Lancaster Urology
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752823

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2021 Amount invested $328.74 1
PY2021 Value of interest $0.00 1
PY2020 Amount invested $328.74 1
PY2020 Value of interest $0.00 1
PY2019 Amount invested $328.74 1
PY2019 Value of interest $0.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

3 records · PY2019–2021

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2021 Innovative Medical Technologies, LLC $328.74 $0.00 Membership Units in Limited Liability Company-Ownership Interest Physician Covered Recipient No dispute reported 06/30/2026 834570393
PY2020 Innovative Medical Technologies, LLC $328.74 $0.00 Membership Units in Limited Liability Company-Ownership Interest Physician Covered Recipient No dispute reported 06/30/2026 748292283
PY2019 Innovative Medical Technologies, LLC $328.74 $0.00 Membership Units in Limited Liability Company-Ownership Interest Physician Covered Recipient No dispute reported 06/30/2026 676681615